3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Brain Neoplasms
41
Carcinoma, Non-Small-Cell Lung
35
Neoplasm Metastasis
32
Pancreatic Neoplasms
30
Prostatic Neoplasms
24
Lung Neoplasms
21
Carcinoma, Hepatocellular
21
Melanoma
16
Breast Neoplasms
12
Liver Neoplasms
10
Glioblastoma
10
Squamous Cell Carcinoma of Head and Neck
8
Carcinoma, Renal Cell
8
Neoplasms
7
Head and Neck Neoplasms
7
Kidney Neoplasms
6
Gliosarcoma
6
Sarcoma
5
Glioma
5
Central Nervous System Neoplasms
5
Uterine Cervical Neoplasms
4
Salivary Gland Neoplasms
4
Colorectal Neoplasms
4
Vulvar Neoplasms
3
Vaginal Neoplasms
3
Recurrence
3
Radiation Injuries
3
Pain
3
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
3
Interventions
pembrolizumab
25
Gemcitabine
21
Nivolumab
17
Cisplatin
17
atezolizumab
14
Carboplatin
11
avelumab
9
vinflunine
7
Ipilimumab
7
Paclitaxel
6
Docetaxel
5
enfortumab vedotin
4
cabazitaxel
4
Pemetrexed
4
Mitomycin
4
cabozantinib
3
Taxes
3
Rogaratinib
3
Magnetic Resonance Spectroscopy
3
Injections
3
Albumin-Bound Paclitaxel
3
tremelimumab
2
sacituzumab govitecan
2
pemigatinib
2
niraparib
2
lenvatinib
2
bempegaldesleukin
2
apatorsen
2
XRP6258
2
Vitamin D
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Transitional Cell
×
Radiosurgery
×
Clear all
NCT03511391
2024-01-23
CHEERS
University Hospital, Ghent
Phase 2
Completed
99 enrolled